Table 3 Cytotoxicity of the tested extracts and doxorubicin towards sensitive and drug-resistant cancer cell lines and normal cells as determined by the resazurin assay
Cell lines | Samples, IC50 values in µg/mL and degrees of resistancea (in bracket) | Doxorubicin | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
AFB | AML | AMS | AMP | EPW | PSL | PSB | PSR | PEF | PEP | ||
CEM/ADR5000 | 29.49 ± 1.77 (1.56) | 5.25 ± 0.38 (9.29) | 6.65 ± 0.22 (18.47) | 23.70 ± 1.64 (5.17) | 37.00 ± 2.17 (1.99) | 18.21 ± 1.45 (1.34) | 14.97 ± 0.97 (0.87) | 10.13 ± 0.88 (0.59) | 8.20 ± 1.02 (11.88) | 18.40 ± 1.42 (5.40) | 108.00 ± 7.92 (975.60) |
MDA-MB-231-pcDNA | >80 | >80 | >80 | >80 | >80 | 52.08 ± 4.98 | 52.66 ± 6.03 | 37.19 ± 2.74 | >80 | >80 | 0.61 ± 0.15 |
MDA-MB-231-BCRP Degree of resistance | >80 | >80 | >80 | >80 | >80 | 61.98 ± 4.31 (1.19) | 47.27 ± 3.76 (0.90) | 46.92 ± 4.89 (1.26) | >80 | >80 | 4.33 ± 0.26 (7.12) |
HCT116 (p53 +/+) | >80 | >80 | >80 | >80 | >80 | 65.21 ± 7.15 | 34.35 ± 1.99 | 28.66 ± 1.62 | >80 | >80 | 0.78 ± 0.16 |
HCT116 (p53 −/−) Degree of resistance | >80 | >80 | >80 | >80 | >80 | 56.97 ± 4.09 (0.87) | 65.68 ± 4.80 (1.91) | 72.01 ± 5.26 (2.51) | >80 | >80 | 2.25 ± 0.04 (2.88) |
U87MG | >80 | >80 | >80 | >80 | >80 | 65.21 ± 5.79 | 52.46 ± 5.22 | 24.80 ± 1.36 | >80 | >80 | 0.59 ± 0.08 |
U87MG.ΔEGFR Degree of resistance | >80 | >80 | >80 | >80 | >80 | 68.65 ± 3.48 (1.05) | 58.70 ± 3.67 (1.12) | 46.91 ± 3.01 (1.89) | >80 | >80 | 3.38 ± 0.32 (5.76) |
HepG2 | 38.69 ± 3.08 (>802.07) | >80 | >80 | >80 | >80 | 46.98 ± 3.17 (>1.70) | 36.39 ± 3.08 (0.62) | 37.56 ± 2.17 (0.80) | >80 | >80 | 2.12 ± 0.52 (>37.74) |
AML12 Degree of resistance | >80 | >80 | >80 | >80 | >80 | >80 | >80 | >80 | >80 | >80 | >80 |